The Use of PET Imaging for Prognostic Integrin α₂β₁ Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses.

ABSTRACT:

Purpose

Growing evidence has demonstrated that aberrant expression of integrin α2β1 might contribute to the invasion, metastasis and drug resistance of non-small cell lung cancer (NSCLC). Thus, the integrin α2β1 targeting ⁶⁸Ga-DOTA-A2B1 tracer was validated in NSCLC in contrast to accumulation of the clinically used ¹⁸F-FDG PET tracer to see if ⁶⁸Ga-DOTA-A2B1-PET imaging can offer a valuable and critical diagnostic imaging criterion for the identification of phenotypes of aggressive lung cancer.

Methods

To verify the prognostic value of integrin α2β1, several quantitative and functional in vitro assays were validated in different NSCLC cell lines (CL1-0, CL1-5, A549 and selected A549⁺⁺ cells). Positron emission tomography (P

SUBMITTER: Huang CW 

PROVIDER: S-EPMC5667422 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature